278 related articles for article (PubMed ID: 34558308)
1. Proton therapy for prostate cancer: current state and future perspectives.
Wu YY; Fan KH
Br J Radiol; 2022 Mar; 95(1131):20210670. PubMed ID: 34558308
[TBL] [Abstract][Full Text] [Related]
2. Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care.
Kamran SC; Light JO; Efstathiou JA
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):509-521. PubMed ID: 30967625
[TBL] [Abstract][Full Text] [Related]
3. Controversies in proton therapy for prostate cancer.
Bryant C; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Su Z; Li Z; Mendenhall NP
Chin Clin Oncol; 2016 Aug; 5(4):55. PubMed ID: 27558255
[TBL] [Abstract][Full Text] [Related]
4. Proton therapy for prostate cancer: A review of the rationale, evidence, and current state.
Royce TJ; Efstathiou JA
Urol Oncol; 2019 Sep; 37(9):628-636. PubMed ID: 30527342
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
6. Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy.
Doyen J; Falk AT; Floquet V; Hérault J; Hannoun-Lévi JM
Cancer Treat Rev; 2016 Feb; 43():104-12. PubMed ID: 26827698
[TBL] [Abstract][Full Text] [Related]
7. Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
Prasanna PG; Rawojc K; Guha C; Buchsbaum JC; Miszczyk JU; Coleman CN
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1325-1340. PubMed ID: 33640423
[TBL] [Abstract][Full Text] [Related]
8. Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?
Gray PJ; Efstathiou JA
Curr Urol Rep; 2013 Jun; 14(3):199-208. PubMed ID: 23546839
[TBL] [Abstract][Full Text] [Related]
9. Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapy.
Pedersen J; Flampouri S; Bryant C; Liang X; Mendenhall N; Li Z; Liu M; Muren LP
Radiother Oncol; 2020 Jan; 142():253-260. PubMed ID: 31630864
[TBL] [Abstract][Full Text] [Related]
10. Clinical controversies: proton therapy for prostate cancer.
Mouw KW; Trofimov A; Zietman AL; Efstathiou JA
Semin Radiat Oncol; 2013 Apr; 23(2):109-14. PubMed ID: 23473687
[TBL] [Abstract][Full Text] [Related]
11. Intelligent ePR system for evidence-based research in radiotherapy: proton therapy for prostate cancer.
Le AH; Liu B; Schulte R; Huang HK
Int J Comput Assist Radiol Surg; 2011 Nov; 6(6):769-84. PubMed ID: 21409498
[TBL] [Abstract][Full Text] [Related]
12. Finding Value for Protons: The Case of Prostate Cancer?
Ojerholm E; Bekelman JE
Semin Radiat Oncol; 2018 Apr; 28(2):131-137. PubMed ID: 29735189
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
Verma V; Mishra MV; Mehta MP
Cancer; 2016 May; 122(10):1483-501. PubMed ID: 26828647
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group.
Iwata H; Ishikawa H; Takagi M; Okimoto T; Murayama S; Akimoto T; Wada H; Arimura T; Sato Y; Araya M; Mizoe JE; Gosho M; Nakamura K; Shirato H; Sakurai H
Cancer Med; 2018 Mar; 7(3):677-689. PubMed ID: 29441697
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of hypofractionated proton therapy with 4 fractions of 5 Gy as a boost to 50 Gy photon therapy for localized prostate cancer.
Johansson S; Isacsson U; Sandin F; Turesson I
Radiother Oncol; 2019 Dec; 141():164-173. PubMed ID: 31431382
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
17. A Monte-Carlo study to assess the effect of 1.5 T magnetic fields on the overall robustness of pencil-beam scanning proton radiotherapy plans for prostate cancer.
Kurz C; Landry G; Resch AF; Dedes G; Kamp F; Ganswindt U; Belka C; Raaymakers BW; Parodi K
Phys Med Biol; 2017 Oct; 62(21):8470-8482. PubMed ID: 29047455
[TBL] [Abstract][Full Text] [Related]
18. Clinical controversies: proton radiation therapy for brain and skull base tumors.
Combs SE; Laperriere N; Brada M
Semin Radiat Oncol; 2013 Apr; 23(2):120-6. PubMed ID: 23473689
[TBL] [Abstract][Full Text] [Related]
19. Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound.
Holtzman AL; Hoppe BS; Letter HP; Bryant C; Nichols RC; Henderson RH; Mendenhall WM; Morris CG; Williams CR; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):465-471. PubMed ID: 26883560
[TBL] [Abstract][Full Text] [Related]
20. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.
Henderson RH; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Li Z; Su Z; Morris CG; Williams CR; Costa J; Mendenhall NP
Acta Oncol; 2013 Apr; 52(3):463-9. PubMed ID: 23477359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
